



Infliximab and its biosimilars

<u>Notification:</u>	<u>Category:</u>	<u>Topic:</u>	<u>What is changing? / Change Description:</u>	<u>Why is Humana making this change? / Change Reason:</u>	<u>Language:</u>	<u>Impacted Products:</u>
<u>8480</u>	<u>HCPCS - Drugs & Biologicals</u>	<u>Louisiana Medicaid: infliximab and its biosimilars – HCPCS J1745, Q5103, Q5104, Q5109 and Q5121</u>	<u>For providers with a specialty other than home infusion therapy, we limit reimbursement of charges for HCPCS J1745, Q5103, Q5104, Q5109 and Q5121 to no more than 1 administration every 2 weeks if billed with a diagnosis of ulcerative colitis (pediatric) for patients 17 years old and younger.</u>	<u>According to the FDA-approved prescribing information and package insert, infliximab is limited to no more than 1 visit every 2 weeks for the indication above.</u>	<u>English</u>	<u>Medicaid- Louisiana</u>
<u>8478</u>	<u>HCPCS - Drugs & Biologicals</u>	<u>Louisiana Medicaid: infliximab and its biosimilars – HCPCS J1745, Q5103, Q5104, Q5109 and Q5121</u>	<u>For providers with a specialty other than home infusion therapy, we limit reimbursement of charges for HCPCS codes J1745, Q5103, Q5104, Q5109 and Q5121 to no more than 1 administration per week for patients 18 years old and older if billed with a diagnosis of ulcerative colitis.</u>	<u>The above limitations are established according to the FDA-approved package insert and prescribing information and pharmaceutical compendia.</u>	<u>English</u>	<u>Medicaid- Louisiana</u>